BioStock: Saniona comments on the approval to initiate epilepsy study

Saniona has received approval to initiate a phase I multiple ascending dose and biomarker study in adults for SAN711, marking a key milestone toward a clinical proof-of-concept trial in children with absence seizures, planned for 2025.
– We are confident in its safety and believe it holds potential not only for this condition but for other epilepsy indications, and possibly beyond epilepsy, says CEO Thomas Feldthus.

Read the full interview with Thomas Feldthus at biostock.se:

https://www.biostock.se/en/2024/09/saniona-comments-on-the-approval-to-initiate-epilepsy-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/